Russia approves first mRNA vaccine for melanoma treatment

The Russian National Medical Research Center for Radiology and Microbiology, together with the National Research Center for Epidemiology and Microbiology "Gamaleja", announced the world’s first approval of an mRNA anti‑tumor vaccine. The vaccine is intended for adult patients with inoperable or metastatic melanoma and is to be used together with immune‑checkpoint inhibitors or as adjuvant therapy after surgical removal of metastases. It is produced individually for each patient based on the genetic profile of the tumour, enabling the immune system to target only cancer cells.

Academician Alexander Gintsburg, director of Gamaleja, highlighted the early clinical results as encouraging but emphasized that the therapy must still pass larger, longer‑term trials to confirm safety and efficacy. The World Health Organization noted that no mRNA cancer vaccine is currently approved for routine use, making this a landmark experimental step in personalized oncology.

If confirmed, the vaccine could mark a new era in cancer treatment, similar to the impact of mRNA COVID‑19 vaccines, but widespread clinical adoption remains contingent on further study.